Tempest Therapeutics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Tempest executed a development collaboration with Hebei Senlang Biotechnology for TPST-4003 (dual-targeting CD19/BCMA CAR-T with CD7-targeted mRNA/LNP delivery), with first patient dosing in Q4 2026 and initial data in H1 2027. Company raised ~$3.4M gross (private placement $1.7M in March 2026 + warrant inducement $1.7M in Q2 2026), appointed two board directors (Drake Richey and John Yee, MD), and ended Q2 2026 with $0.8M cash (down from $7.7M at December 31, 2025). YTD net loss was $32.9M including $22.1M acquired IPR&D expense from February 2026 asset acquisition; cash burn was $10.4M for six months.
Why this rating
At $30.1M market cap, $3.4M fundraising and Senlang partnership meaningfully advance lead program; however critical cash depletion ($0.8M remaining) and massive accumulated deficit ($275.3M) create near-term existential risk requiring immediate additional capital.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.